Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brompheniramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.88 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.88 |
| ▸ | LMNA | P02545 | 4/20 | 0.88 |
| ▸ | HTR2A | P28223 | 3/20 | 0.88 |
| ▸ | SCN1A | P35498 | 3/20 | 0.88 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.88 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.88 |
| ▸ | THPO | P40225 | 2/20 | 0.88 |
| ▸ | DRD1 | P21728 | 2/20 | 0.88 |
| ▸ | HTR2C | P28335 | 2/20 | 0.88 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brompheniramine SCHEMBL28086361 | 1.00 | CHRM2 (0.88) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Dexbrompheniramine SCHEMBL3744666 | 1.00 | CHRM2 (0.88) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Brompheniramine SCHEMBL4075265 | 0.99 | CHRM2 (0.85) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Dexbrompheniramine SCHEMBL29345 | 0.94 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Brompheniramine SCHEMBL4314531 | 0.94 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL4220 | 0.94 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL4219 | 0.94 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Dexchlorpheniramine SCHEMBL3538 | 0.94 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL20956397 | 0.94 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Dexbrompheniramine SCHEMBL15516617 | 0.94 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | claimed |
| WO-1992004021-A1 | METHOD FOR PROVIDING IMPROVED ANALGESIC EFFECT | RICHARDSON VICKS INC. (US) | 1992-03-19 | — | — | WO | claimed |
| US-11628144-B2 | Iniparib formulations and uses thereof | TRIACT THERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230113351-A1 | COMPOSITIONS AND METHODS FOR MANAGING DISORDERS | DIAMOND THERAPEUTICS INC. (CA) | 2023-04-13 | — | — | US | disclosed |
| EP-3917537-A1 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL, AND/OR MOOD DISORDERS | Diamond Therapeutics Inc. (CA) | 2021-12-08 | — | — | EP | disclosed |
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | TRIACT THERAPEUTICS, INC. | 2020-09-24 | — | — | US | disclosed |
| WO-2020157569-A1 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL, AND/OR MOOD DISORDERS | DIAMOND THERAPEUTICS INC. (CA) | 2020-08-06 | — | — | WO | disclosed |
| EP-3687501-A1 | INIPARIB FORMULATIONS AND USES THEREOF | Triact Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019067991-A1 | INIPARIB FORMULATIONS AND USES THEREOF | TRIACT THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| CN-104168905-B | Use of Bifidobacterium lactis B L-04 for treating respiratory diseases | 杜邦营养生物科学有限公司 | 2018-12-04 | — | — | CN | disclosed |
| EP-2323627-A1 | NOVEL RAPID-EFFECT PHARMACEUTICAL FORMS AND USES OF RESULTING PHARMACEUTICAL COMPOSITIONS | Bionetwork (FR) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010007232-A1 | NOVEL RAPID-EFFECT PHARMACEUTICAL FORMS AND USES OF RESULTING PHARMACEUTICAL COMPOSITIONS | BIONETWORK (FR) | 2010-01-21 | — | — | WO | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| CN-1809383-A | Recombinant IL-9 antibodies and uses thereof | MEDIMMUNE INC (US) | 2006-07-26 | — | — | CN | disclosed |
| US-7001886-B2 | Hot melt method for preparing diphenhydramine tannate | JAME FINE CHEMICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040198667-A1 | Hot melt method for preparing diphenhydramine tannate | JAME FINE CHEMICALS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-1997004749-A1 | METHOD FOR PREPARING DRY PHARMACEUTICAL FORMS, AND RESULTING PHARMACEUTICAL COMPOSITIONS | LABORATOIRES EFFIK (FR) | 1997-02-13 | — | — | WO | disclosed |
| EP-0717624-A1 | COMPOSITIONS CONTAINING AN AMINO ACID SALT OF PROPIONIC ACID NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND CAFFEINE | THE PROCTER & GAMBLE COMPANY (US) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007079-A1 | COMPOSITIONS CONTAINING AN AMINO ACID SALT OF PROPIONIC ACID NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND CAFFEINE | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-16 | — | — | WO | disclosed |
| WO-1992004021-A1 | METHOD FOR PROVIDING IMPROVED ANALGESIC EFFECT | RICHARDSON VICKS INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | INPP5B, INPPL1, PARP3 | HRH1 4430/4885CHRM2 4465/4885SLC6A2 2892/4885 |
| US-20230113351-A1 | COMPOSITIONS AND METHODS FOR MANAGING DISORDERS | HTR1A, HTR5A, HTR2A | HRH1 197/4885CHRM2 85/4885SLC6A2 34/4885 |
| US-11628144-B2 | Iniparib formulations and uses thereof | INPP5B, INPPL1, PARP3 | HRH1 4430/4885CHRM2 4465/4885SLC6A2 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.